Jan Welink

1.6k total citations
25 papers, 459 citations indexed

About

Jan Welink is a scholar working on Pediatrics, Perinatology and Child Health, Economics and Econometrics and Statistics and Probability. According to data from OpenAlex, Jan Welink has authored 25 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pediatrics, Perinatology and Child Health, 8 papers in Economics and Econometrics and 8 papers in Statistics and Probability. Recurrent topics in Jan Welink's work include Pharmaceutical studies and practices (9 papers), Pharmaceutical Economics and Policy (8 papers) and Statistical Methods in Clinical Trials (8 papers). Jan Welink is often cited by papers focused on Pharmaceutical studies and practices (9 papers), Pharmaceutical Economics and Policy (8 papers) and Statistical Methods in Clinical Trials (8 papers). Jan Welink collaborates with scholars based in Netherlands, Germany and United States. Jan Welink's co-authors include Jan B. Vermorken, H. Möller, D.M. Barends, Hans E. Junginger, Vinod P. Shah, M Olling, Gordon L. Amidon, K.K. Midha, W. J. F. van der Vijgh and Henrike Potthast and has published in prestigious journals such as Journal of the American Society of Nephrology, Journal of Pharmaceutical Sciences and Clinical Pharmacology & Therapeutics.

In The Last Decade

Jan Welink

24 papers receiving 441 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan Welink Netherlands	11	157	141	99	76	72	25	459
Mira Symillides Greece	19	106 0.7×	455 3.2×	149 1.5×	81 1.1×	115 1.6×	28	718
Henrike Potthast Germany	10	41 0.3×	241 1.7×	55 0.6×	51 0.7×	110 1.5×	20	421
Paul Seo United States	16	115 0.7×	347 2.5×	101 1.0×	204 2.7×	109 1.5×	24	779
Donato Teutonico France	12	111 0.7×	99 0.7×	106 1.1×	125 1.6×	29 0.4×	22	674
Sandra Suarez‐Sharp United States	11	57 0.4×	337 2.4×	60 0.6×	139 1.8×	97 1.3×	22	505
B Booth United States	5	173 1.1×	41 0.3×	80 0.8×	88 1.2×	20 0.3×	17	535
Binfeng Xia United States	12	112 0.7×	189 1.3×	79 0.8×	96 1.3×	66 0.9×	19	470
Nikunjkumar Patel United Kingdom	19	99 0.6×	373 2.6×	73 0.7×	193 2.5×	106 1.5×	36	795
Nam Atiqur Rahman United States	8	158 1.0×	41 0.3×	114 1.2×	114 1.5×	20 0.3×	18	609
Manuela Grimstein United States	9	145 0.9×	51 0.4×	172 1.7×	93 1.2×	26 0.4×	14	535

Countries citing papers authored by Jan Welink

Since Specialization

Citations

This map shows the geographic impact of Jan Welink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Welink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Welink more than expected).

Fields of papers citing papers by Jan Welink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Welink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Welink. The network helps show where Jan Welink may publish in the future.

Co-authorship network of co-authors of Jan Welink

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Welink. A scholar is included among the top collaborators of Jan Welink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Welink. Jan Welink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schug, Barbara, Erem Bilensoy, Jack Cook, et al.. (2025). The Global Bioequivalence Harmonisation Initiative (GBHI): Report of the sixth international EUFEPS/PQRI conference. European Journal of Pharmaceutical Sciences. 212. 107129–107129.

Mehta, Minesh P., Barbara Schug, Wenlei Jiang, et al.. (2023). The Global Bioequivalence Harmonisation Initiative (GBHI): Report of the fifth international EUFEPS/AAPS conference. European Journal of Pharmaceutical Sciences. 190. 106566–106566. 5 indexed citations

Mehta, Minesh P., Angelica Dorantes, Georg Hempel, et al.. (2021). The Global Bioequivalence Harmonisation Initiative (GBHI): Report of EUFEPS/AAPS fourth conference. European Journal of Pharmaceutical Sciences. 167. 105987–105987. 9 indexed citations

Chen, Mei‐Ling, Henning Blume, Minesh P. Mehta, et al.. (2018). Summary report of second EUFEPS/AAPS conference on global harmonization in bioequivalence. European Journal of Pharmaceutical Sciences. 127. 24–28. 9 indexed citations

Chen, Mei‐Ling, Henning Blume, Barbara M. Davit, et al.. (2017). The Global Bioequivalence Harmonization Initiative: Summary report for EUFEPS international conference. European Journal of Pharmaceutical Sciences. 111. 153–157. 19 indexed citations

Gordon, John, Jan Welink, Henrike Potthast, et al.. (2016). Interchangeability between First-Line Generic Antiretroviral Products Prequalified by WHO using Adjusted Indirect Comparisons. Antiviral Therapy. 22(2). 135–144. 3 indexed citations

Gordon, John, Henrike Potthast, Marc Maliepaard, et al.. (2016). Assessment of the interchangeability between generics. Generics and Biosimilars Initiative Journal. 5(2). 55–59. 4 indexed citations

Gordon, John, Henrike Potthast, Jan Welink, et al.. (2015). Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons. European Journal of Clinical Pharmacology. 71(9). 1083–1089. 6 indexed citations

Gordon, John, Jan Welink, Henrike Potthast, et al.. (2014). Adjusted Indirect Treatment Comparison of the Bioavailability of WHO-Prequalified First-Line Generic Antituberculosis Medicines. Clinical Pharmacology & Therapeutics. 96(5). 580–588. 10 indexed citations

10.

Welink, Jan, John Gordon, & Matthias Stahl. (2013). Selection of the comparator product in the World Health Organisation Prequalification of Medicines Programme. Journal of Generic Medicines The Business Journal for the Generic Medicines Sector. 10(3-4). 193–204. 3 indexed citations

11.

Gordon, John, et al.. (2012). Statistical approaches to indirectly compare bioequivalence between generics: a comparison of methodologies employing artemether/lumefantrine 20/120 mg tablets as prequalified by WHO. European Journal of Clinical Pharmacology. 68(12). 1611–1618. 14 indexed citations

12.

Garofolo, Fabio, Brian Booth, C.T. Viswanathan, et al.. (2012). Conference Report: Us Fda/Ema Harmonization of Their Bioanalytical Guidance/Guideline And Activities of The Global Bioanalytical Consortium. Bioanalysis. 4(3). 231–236. 15 indexed citations

13.

Maliepaard, Marc, Yechiel A. Hekster, A.C. Kappelle, et al.. (2010). Switching to generic anti-epileptic medicines : A regulatory perspective. University of Groningen research database (University of Groningen / Centre for Information Technology). 70(6). 918–931. 1 indexed citations

14.

Maliepaard, Marc, Yechiel A. Hekster, A.C. Kappelle, et al.. (2009). Requirements for generic anti-epileptic medicines: a regulatory perspective. Journal of Neurology. 256(12). 1966–1971. 6 indexed citations

15.

Welink, Jan, Gordon L. Amidon, Hans E. Junginger, et al.. (2004). Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol. Journal of Pharmaceutical Sciences. 93(8). 1945–1956. 139 indexed citations

16.

Verschraagen, Miranda, et al.. (2001). Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography B Biomedical Sciences and Applications. 753(2). 293–302. 19 indexed citations

17.

Welink, Jan, et al.. (1999). Anatomical and physiological differences betweenvarious species used in studies on the pharmacokinetics and toxicology of xenobiotics. A review ofliterature. 41 indexed citations

18.

Giaccone, Giuseppe, Sabine C. Linn, Jan Welink, et al.. (1997). A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.. Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam). 3(11). 2005–15. 71 indexed citations

19.

Welink, Jan, et al.. (1996). Determination of the two diastereoisomers of lobaplatin (D-19466) in plasma ultrafiltrate of cancer patients with a normal or an impaired kidney or liver function by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B Biomedical Sciences and Applications. 675(1). 107–111. 17 indexed citations

20.

Dorrestein, Gerry M., Jan Welink, & N. Haagsma. (1990). Pharmacokinetic differences for doxycycline between racing pigeons (Columba livia) and collared doves (Streptopelia decaocto) and the effect of a salmonella infection.. 132–143. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact